Hemostasis And Tissue Sealing Agents Market Size, Industry Report, 2026

Posted by Marsh William on May 29th, 2019

The global Hemostasis And Tissue Sealing Agents Market size is expected to reach USD 10.34 billion by 2026, according to a new report by Grand View Research, Inc. It is projected to register a CAGR of 8.7% during the forecast period. The agents have gained popularity over time due to their ability to prevent blood loss. Rapid growth of minimal invasive technology and demand for faster recovery by patients is expected to promote market growth over the forecast period.

According to the Centers for Disease Control and Prevention (CDC), approximately 150 million of American population is currently suffering from at least one chronic condition, which leads to surgeries and even mortality at times. An estimate over the rising incidence was made by the CDC, which concluded that over 48% of the entire American population is expected to suffer by chronic condition.

The hemostasis and tissue sealing agents market is expected to witness lucrative growth over the next seven years owing to, an increase in demand supported by rising surgery volumes. Growth in geriatric population and prevalence of chronic conditions are the impact rendering drivers for this industry.

Further key findings from the report suggest:

  • The hemostats market is expected to expand at a CAGR of over 8.7% over the forecast period owing to the rise in global volume of surgeries and applicability of the product across a variety of surgeries to avoid occurrence of hypovolemic shock, thrombocytopenia, blood transfusions, and post-operative complications
  • Flowable hemostats are a combination of active and mechanical agents. They function by blocking blood flow and also converting fibrinogen into fibrin for coagulation. This segment is expected to witness a lucrative CAGR of over 10.0% from 2018 to 2026
  • Some key players operating in the hemostasis and tissue sealing agents market include Johnson & Johnson; CryoLife Inc.; Pfizer; C R Bard; B Braun; Covidien; and Smith & Nephew. Market participants are involved in technological advancements to ensure sustainability and regional presence
  • For instance, in March 2015, Ethicon announced higher efficiency of EVARREST fibrin sealant patch as compared to its substitute, TachoSil patch (Baxter). Further study would be conducted at the St. Vincent Heart Centre of Indiana to understand added advantages that the product can offer.

Browse Details of Report @ https://www.grandviewresearch.com/industry-analysis/hemostasis-tissue-sealing-agents-market

Like it? Share it!


Marsh William

About the Author

Marsh William
Joined: August 11th, 2017
Articles Posted: 478

More by this author